Caladrius Biosciences, Inc. CLBS Cash Flow

Caladrius biosciences, inc. (CLBS)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-18,973	-19,352	-17,956	-16,608	-15,549	-16,168	-15,506	-15,505	27,037	22,228	19,034	15,294	-31,055	-33,309	-60,448	-64,553	-73,826	-81,010	-59,472	-65,256	-60,867	-55,466	-56,494	-48,594	-44,451	-39,485	-42,110	-41,229	-66,026	-66,369	-79,879	-78,974	-56,089	-56,582	0	0	0
Income from discontinued operations
-	-	-	-	-	-	-	-	-	38,399	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30,267	0	0	0	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation
1,315	1,295	1,219	1,131	2,853	2,453	2,362	2,258	1,714	1,963	1,379	2,709	1,318	1,773	3,457	2,501	6,885	9,750	10,836	13,688	11,031	11,209	10,367	9,177	8,513	6,838	6,653	6,471	6,454	6,712	7,572	7,164	10,723	10,266	0	0	0
Depreciation and amortization
63	65	67	91	155	225	295	347	360	372	383	391	-187	450	1,144	1,684	2,819	2,686	2,501	2,453	2,346	2,186	1,986	1,760	1,495	1,605	1,587	1,608	1,720	1,550	1,379	1,292	-378	1,440	0	0	0
Amortization of preferred stock discount and issuance cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,609	1,731	1,983	2,236	2,440	0	0	0
Changes in fair value of derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	77	313	330	296	373	482	1,913	2,446	2,096	0	0	0
Change in acquisition-related contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
(Gain) loss on disposal of assets
-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion on marketable securities
0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Write off of acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,150	0	0	0
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Contributions paid with common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	607	0	0	0
Bad debt recovery
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	0	0	0	-	-180	-169	-254	87	0	0	0
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Amortization/accretion on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	95	121	84	81	51	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Prepaid and other current assets
-815	-238	-21	-67	-41	-261	-506	-675	-924	-1,014	-303	-474	-660	-457	-836	-909	-704	-872	-935	1,455	2,444	2,768	2,890	1,512	837	758	845	172	131	178	122	733	462	350	0	0	0
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	44	101	255	1,369	645	-545	206	-1,219	29	1,198	641	1,534	765	573	-448	-328	-39	554	611	507	47	443	0	0	0
Deferred costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	364	344	1,206	940	2,145	1,296	1,612	2,001	-65	157	81	-1,129	685	465	1,227	350	-2,194	647	0	0	0
Unearned revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,909	1,011	1,858	1,812	3,472	2,517	2,618	2,468	217	348	100	-1,425	264	178	739	292	1,781	948	0	0	0
Other assets
-646	-504	-381	-314	-292	-291	-165	-126	-217	-148	-195	-255	-161	-222	-424	-441	-430	-286	-107	-712	-604	-613	-354	285	234	204	-2,602	-2,569	-2,571	-2,414	0	0	0	-	-	-	-
Due to PCT
-	-	-	-	-	-	-	-	-	1,682	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable, accrued liabilities and other liabilities
-1,672	-1,864	-1,693	-3,212	-5,818	-5,901	5,508	4,122	4,509	5,667	-5,758	-3,484	-3,578	-3,145	-6,278	-4,583	1,157	79	6,100	4,208	922	469	-347	1,574	2,162	2,916	1,745	440	-798	1,677	271	-484	3,555	-486	0	0	0
Net cash used in operating activities - continuing operations
-	-	-	-	-	-	-	-	-	-20,238	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-18,759	0	0	0	-	-	-	-
Net cash used in operating activities - discontinued operations
-	-	-	-	-	-	-	-	-	-638	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,907	0	0	0	-	-	-	-
Net cash used in operating activities
-17,637	-18,882	-17,704	-18,007	-19,173	-19,986	-20,913	-22,483	-17,087	-20,876	-20,281	-19,668	-25,727	-23,667	-29,019	-32,006	-33,046	-39,258	-41,434	-46,216	-49,881	-46,895	-43,355	-36,482	-31,219	-27,101	-29,362	-26,125	-23,094	-13,852	-7,633	-8,514	-8,626	-20,927	0	0	0
Cash flows from investing activities:
Purchase of marketable securities
16,674	32,938	41,811	57,338	61,810	69,690	68,624	62,057	84,302	60,158	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of marketable securities
40,469	54,370	56,874	62,806	64,608	62,567	80,901	70,355	56,837	33,873	0	0	0	-	-	-	-	13,066	8,399	7,962	7,962	913	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash Acquired from Acquisition
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	320	0	0	0
Change in restricted cash used as collateral for notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	0	0	0
Acquisition of property and equipment
2	0	0	123	125	134	150	48	74	135	149	128	124	1,099	1,680	2,451	3,886	3,185	3,305	3,020	2,762	3,657	4,668	4,862	3,877	2,691	1,282	623	452	531	265	362	-0	574	0	0	0
Net cash (used in) provided by investing activities - continuing operations
-	-	-	-	-	-	-	-	-	41,460	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,748	0	0	0	-	-	-	-
Net cash used in investing activities - discontinued operations
-	-	-	-	-	-	-	-	-	-189	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,660	0	0	0	-	-	-	-
Net cash provided by investing activities
23,793	21,432	15,063	5,395	5,223	-4,707	14,593	15,091	40,253	41,271	22,502	25,683	-1,975	-2,849	2,403	-138	-3,950	3,798	-8,110	-5,195	-2,792	-10,736	-5,290	-5,731	-3,877	-2,691	7,827	8,136	6,144	6,088	-1,614	2,045	939	-2,054	0	0	0
Cash flows from financing activities:
Proceeds from exercise of options
-	-	-	-	-	355	354	341	53	13	13	13	0	0	0	0	0	-	-	-	-	271	335	380	222	150	0	0	0	-	-	-	-	-	-	-	-
Tax withholding payments on net share settlement equity awards
148	130	130	130	488	403	403	403	379	358	429	429	95	72	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of common stock
313	1,313	1,071	1,781	2,031	1,031	1,021	2,711	2,460	5,702	5,588	13,788	13,705	11,560	11,985	1,385	30,155	36,471	41,572	42,697	18,491	16,710	48,493	54,637	61,636	58,736	25,786	20,725	11,468	16,428	12,145	25,196	25,251	21,152	0	0	0
Repayment of long-term debt
-	-	-	-	-	-	-	-	-	5,651	5,651	8,651	3,756	9,348	9,348	6,348	6,348	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of mortgage loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,236	3,288	214	211	201	205	195	187	196	181	178	200	149	0	0	0
Proceeds of bank loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from notes payable
-	-	-	-	-	-	-	-	-	401	835	835	835	803	368	366	1,115	1,087	1,137	1,576	1,209	1,827	2,108	2,161	1,999	1,041	1,152	664	443	666	223	223	-6,875	149	0	0	0
Repayment of notes payable
-	-	-	-	-	159	359	578	838	965	1,079	1,062	888	1,030	766	849	1,030	954	1,263	1,248	1,192	1,097	907	849	585	503	585	377	455	440	235	105	-2,030	180	0	0	0
Proceeds From Licensing Agreements, Milestone Payments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of debt to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,000	0	0	0
Repayment of preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,394	0	0	0	-	-	-	-
Sale of ownership interest in subsidiary
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	228	0	0	0	-	-	-	-
Advance payment received from potential PCT sale
-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities - continuing operations
-	-	-	-	-	-	-	-	-	-858	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,111	0	0	0	-	-	-	-
Net cash used in financing activities - discontinued operations
-	-	-	-	-	-	-	-	-	-74	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-8,370	0	0	0	-	-	-	-
Change in warrant liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
165	1,183	941	1,641	1,766	824	613	2,071	-8,555	-932	-747	4,331	14,274	20,903	21,180	13,633	43,292	36,604	41,446	54,757	30,446	30,672	63,840	60,355	67,203	62,189	22,214	14,394	4,261	8,741	13,975	19,946	20,174	20,069	0	0	0
Net increase in cash and cash equivalents
6,321	3,733	-1,700	-10,971	-12,184	-23,869	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (decrease) increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	19,463	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impact of changes of foreign exchange rates
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14	-260	-65	-25	46	0	0	0
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-18,511	6,294	1,144	-8,098	3,346	-22,228	-26,959	15,195	18,142	32,106	32,396	766	-3,539	-12,621	992	4,466	13,411	12,462	-2,866	0	0	0
Supplemental Disclosure of Cash Flow Information:
Interest
-	-	-	-	-	5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest
-	-	-	-	-	-	-	-	-	-	1,555	1,547	979	1,823	1,349	1,726	2,099	1,497	995	781	511	232	430	344	271	274	319	654	1,247	1,771	1,939	1,432	2,108	1,522	0	0	0
Proceeds from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	1,720	2,622	4,296	4,197	3,028	2,804	6,710	6,710	6,604	0	0	0	-	-	-	-
Taxes
-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	258	1,288	1,813	2,100	1,497	296	109	1,119	0	0	0
Acquisition of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Capitalized interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	182	303	278	309	384	0	0	0
Common stock and warrants issued with the acquisition of PCT
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,200	0	0	0
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,026	1,752	2,269	3,253	3,511	0	0	0
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	175	302	404	544	748	0	0	0